Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Hilbert

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Nature Biotechnology|January 11, 2012
The discovery and development of belimumab: the anti-BLyS-lupus connectionWilliam Stohl, David M Hilbert
Leukemia & Lymphoma|October 23, 2002
B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseasesBernardetta Nardelli, Paul A Moore, Yuling Li, et al.
Experimental Hematology|February 2, 2002
BLyS and BLyS receptor expression in non-Hodgkin's lymphomaJavier Briones, John M Timmerman, David M Hilbert, et al.
Clinical Immunology (Orlando, Fla.)|November 5, 2003
B lymphocytes from individuals with common variable immunodeficiency respond to B lymphocyte stimulator (BLyS protein) in vitroDonn M Stewart, Michael J McAvoy, David M Hilbert, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 11, 2002
Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediatorsBenjamin L Hsu, Susan M Harless, R Coleman Lindsley, et al.
Arthritis Research & Therapy|December 17, 2005
B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levelsChristopher E Collins, Amanda L Gavin, Thi-Sau Migone, et al.
Nature Immunology|August 3, 2002
DCs induce CD40-independent immunoglobulin class switching through BLyS and APRILMikhail B Litinskiy, Bernardetta Nardelli, David M Hilbert, et al.
Arthritis and Rheumatism|March 2, 2006
Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapseGeraldine Cambridge, William Stohl, Maria J Leandro, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 3, 2019
Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T CellsHaiying Qin, Justin P Edwards, Liubov Zaritskaya, et al.
Arthritis and Rheumatism|December 16, 2003
B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observationsWilliam Stohl, Samy Metyas, Soon-Min Tan, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Nature Biotechnology|January 11, 2012
The discovery and development of belimumab: the anti-BLyS-lupus connectionWilliam Stohl, David M Hilbert
Leukemia & Lymphoma|October 23, 2002
B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseasesBernardetta Nardelli, Paul A Moore, Yuling Li, et al.
Experimental Hematology|February 2, 2002
BLyS and BLyS receptor expression in non-Hodgkin's lymphomaJavier Briones, John M Timmerman, David M Hilbert, et al.
Clinical Immunology (Orlando, Fla.)|November 5, 2003
B lymphocytes from individuals with common variable immunodeficiency respond to B lymphocyte stimulator (BLyS protein) in vitroDonn M Stewart, Michael J McAvoy, David M Hilbert, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 11, 2002
Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediatorsBenjamin L Hsu, Susan M Harless, R Coleman Lindsley, et al.
Arthritis Research & Therapy|December 17, 2005
B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levelsChristopher E Collins, Amanda L Gavin, Thi-Sau Migone, et al.
Nature Immunology|August 3, 2002
DCs induce CD40-independent immunoglobulin class switching through BLyS and APRILMikhail B Litinskiy, Bernardetta Nardelli, David M Hilbert, et al.
Arthritis and Rheumatism|March 2, 2006
Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapseGeraldine Cambridge, William Stohl, Maria J Leandro, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 3, 2019
Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T CellsHaiying Qin, Justin P Edwards, Liubov Zaritskaya, et al.
Arthritis and Rheumatism|December 16, 2003
B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observationsWilliam Stohl, Samy Metyas, Soon-Min Tan, et al.
Pageof 2